These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28750139)

  • 1. Is mitotic rate still useful in the management of patients with thin melanoma?
    Tejera-Vaquerizo A; Pérez-Cabello G; Marínez-Leborans L; Gallego E; Oliver-Martínez V; Martín-Cuevas P; Arias-Santiago S; Aneiros-Fernández J; Herrera-Acosta E; Traves V; Herrera-Ceballos E; Nagore E
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2025-2029. PubMed ID: 28750139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts.
    Isaksson K; Nielsen K; Mikiver R; Nieweg OE; Scolyer RA; Thompson JF; Ingvar C
    J Surg Oncol; 2018 Sep; 118(4):599-605. PubMed ID: 30196533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma.
    Hieken TJ; Grotz TE; Comfere NI; Inselman JW; Habermann EB
    Melanoma Res; 2015 Apr; 25(2):157-63. PubMed ID: 25647736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study.
    Tejera-Vaquerizo A; Ribero S; Puig S; Boada A; Paradela S; Moreno-Ramírez D; Cañueto J; de Unamuno B; Brinca A; Descalzo-Gallego MA; Osella-Abate S; Cassoni P; Carrera C; Vidal-Sicart S; Bennássar A; Rull R; Alos L; Requena C; Bolumar I; Traves V; Pla Á; Fernández-Orland A; Jaka A; Fernández-Figueres MT; Hilari JM; Giménez-Xavier P; Vieira R; Botella-Estrada R; Román-Curto C; Ferrándiz L; Iglesias-Pena N; Ferrándiz C; Malvehy J; Quaglino P; Nagore E;
    Cancer Med; 2019 Aug; 8(9):4235-4244. PubMed ID: 31215168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Mitotic Rate Predicts Sentinel Lymph Node Involvement in Thin Melanomas.
    Skochdopole AJ; Kutlu OC; Engelhardt KE; Lancaster WP; Abbott AM; Camp ER
    J Surg Res; 2020 Dec; 256():198-205. PubMed ID: 32711176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.
    Wat H; Senthilselvan A; Salopek TG
    J Am Acad Dermatol; 2016 Jan; 74(1):94-101. PubMed ID: 26542815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph node status in melanoma: prognostic value in a tertiary hospital and correlation with mitotic activity.
    Mahiques Santos L; Oliver Martinez V; Alegre de Miquel V
    Actas Dermosifiliogr; 2014; 105(1):60-8. PubMed ID: 24021663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database.
    Conic RRZ; Ko J; Damiani G; Funchain P; Knackstedt T; Vij A; Vidimos A; Gastman BR
    J Am Acad Dermatol; 2019 Feb; 80(2):441-447. PubMed ID: 30240775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How does the mitotic index impact patients with T1 melanoma? Comparison between the 7th and 8th edition of the American Joint Committee on Cancer melanoma staging system.
    Antonialli AZ; Bertolli E; de Macedo MP; Pinto CAL; Calsavara VF; Neto JPD
    An Bras Dermatol; 2020; 95(6):691-695. PubMed ID: 33008658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.
    Kesmodel SB; Karakousis GC; Botbyl JD; Canter RJ; Lewis RT; Wahl PM; Terhune KP; Alavi A; Elder DE; Ming ME; Guerry D; Gimotty PA; Fraker DL; Czerniecki BJ; Spitz FR
    Ann Surg Oncol; 2005 Jun; 12(6):449-58. PubMed ID: 15864482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.
    Rousseau DL; Ross MI; Johnson MM; Prieto VG; Lee JE; Mansfield PF; Gershenwald JE
    Ann Surg Oncol; 2003 Jun; 10(5):569-74. PubMed ID: 12794025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
    Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
    Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it Necessary to Perform Sentinel Lymph Node Biopsy in Thin Melanoma? A Retrospective Single Center Analysis.
    Kocsis A; Karsko L; Kurgyis Z; Besenyi Z; Pavics L; Dosa-Racz E; Kis E; Baltas E; Ocsai H; Varga E; Bende B; Varga A; Mohos G; Korom I; Varga J; Kemeny L; Nemeth IB; Olah J
    Pathol Oncol Res; 2020 Jul; 26(3):1861-1868. PubMed ID: 31792874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model.
    Sondak VK; Taylor JM; Sabel MS; Wang Y; Lowe L; Grover AC; Chang AE; Yahanda AM; Moon J; Johnson TM
    Ann Surg Oncol; 2004 Mar; 11(3):247-58. PubMed ID: 14993019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitotic rate for thin melanomas: should a single mitotic figure warrant a sentinel lymph node biopsy?
    Kirkland EB; Zitelli JA
    Dermatol Surg; 2014 Sep; 40(9):937-45. PubMed ID: 25072127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy.
    Bartlett EK; Gimotty PA; Sinnamon AJ; Wachtel H; Roses RE; Schuchter L; Xu X; Elder DE; Ming M; Elenitsas R; Guerry D; Kelz RR; Czerniecki BJ; Fraker DL; Karakousis GC
    Ann Surg Oncol; 2014 Feb; 21(2):643-9. PubMed ID: 24121883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8
    Egger ME; Stevenson M; Bhutiani N; Jordan AC; Scoggins CR; Philips P; Martin RC; McMasters KM
    J Am Coll Surg; 2019 Apr; 228(4):466-472. PubMed ID: 30660817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases.
    Mandalà M; Galli F; Cattaneo L; Merelli B; Rulli E; Ribero S; Quaglino P; De Giorgi V; Pigozzo J; Sileni VC; Chirco A; Ferrucci PF; Occelli M; Imberti G; Piazzalunga D; Massi D; Tondini C; Queirolo P;
    J Am Acad Dermatol; 2017 Feb; 76(2):264-273.e2. PubMed ID: 27847125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.